See more : MPHB Capital Berhad (5237.KL) Income Statement Analysis – Financial Results
Complete financial analysis of iBio, Inc. (IBIO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of iBio, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Tai Industries Limited (TAIIND.BO) Income Statement Analysis – Financial Results
- Mishra Dhatu Nigam Limited (MIDHANI.BO) Income Statement Analysis – Financial Results
- Zhejiang Jinfei Kaida Wheel Co.,Ltd. (002863.SZ) Income Statement Analysis – Financial Results
- Bally, Corp. (BLYQ) Income Statement Analysis – Financial Results
- Blueprint Medicines Corporation (0HOJ.L) Income Statement Analysis – Financial Results
iBio, Inc. (IBIO)
About iBio, Inc.
iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties on a catalog and custom basis; and offers a range of process development, manufacturing, filling and finishing, and bio analytic services. iBio, Inc. has a license agreement with Planet Biotechnology, Inc. to develop therapeutics for infectious diseases; collaboration agreement with The Texas A&M University System for the development of coronavirus disease 2019 vaccine candidates; license agreement with the University of Natural Resources and Life Sciences, Vienna; and collaboration agreement with CC-Pharming Ltd. The company is headquartered in Bryan, Texas.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 225.00K | 0.00 | 2.38M | 2.37M | 1.64M | 2.02M | 444.00K | 394.00K | 948.00K | 1.85M | 205.00K | 1.01M | 1.28M | 520.08K | 0.00 | 1.18M | 987.06K | 896.27K |
| Cost of Revenue | 0.00 | 1.11M | 216.00K | 1.46M | 703.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 500.84K | 485.13K | 445.72K |
| Gross Profit | 225.00K | -1.11M | 2.17M | 909.00K | 935.00K | 2.02M | 444.00K | 394.00K | 948.00K | 1.85M | 205.00K | 1.01M | 1.28M | 520.08K | 0.00 | 675.77K | 501.93K | 450.55K |
| Gross Profit Ratio | 100.00% | 0.00% | 90.94% | 38.34% | 57.08% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% | 57.43% | 50.85% | 50.27% |
| Research & Development | 5.19M | 10.33M | 17.73M | 9.99M | 3.21M | 5.47M | 3.99M | 4.12M | 3.16M | 3.50M | -150.00K | 3.43M | 4.98M | 3.08M | 2.52M | 797.40K | 550.00K | 673.23K |
| General & Administrative | 11.67M | 19.02M | 34.13M | 22.03M | 12.43M | 12.33M | 10.69M | 10.55M | 7.69M | 5.02M | 4.20M | 4.24M | 5.62M | 7.09M | 2.07M | 1.80M | 1.82M | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 11.67M | 19.02M | 34.13M | 22.03M | 12.43M | 12.33M | 10.69M | 10.55M | 7.69M | 5.02M | 4.20M | 4.24M | 5.62M | 7.09M | 2.07M | 1.80M | 1.82M | 1.44M |
| Other Expenses | 0.00 | 0.00 | 13.00K | 12.00K | 10.00K | 16.00K | 19.00K | 25.00K | 21.00K | 32.00K | 45.00K | 30.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.44M |
| Operating Expenses | 16.86M | 29.34M | 51.86M | 32.02M | 15.64M | 17.81M | 14.67M | 14.67M | 10.84M | 8.52M | 4.05M | 7.67M | 10.60M | 10.17M | 4.59M | 2.60M | 2.37M | 2.12M |
| Cost & Expenses | 16.86M | 29.34M | 52.07M | 33.48M | 15.64M | 17.81M | 14.67M | 14.67M | 10.84M | 8.52M | 4.05M | 7.67M | 10.60M | 10.17M | 4.59M | 3.10M | 2.85M | 2.56M |
| Interest Income | 363.00K | 130.00K | 178.00K | 140.00K | 15.00K | 75.00K | 15.00K | 39.00K | 22.00K | 9.00K | 130.00K | 9.00K | 11.67K | 12.62K | 12.73K | 20.42K | 0.00 | 0.00 |
| Interest Expense | 172.00K | 0.00 | 1.41M | 2.45M | 2.47M | 1.90M | 1.92M | 1.93M | 807.00K | 0.00 | 122.00K | 90.00K | 62.85K | 50.50K | 13.11K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.25M | 1.11M | 3.79M | 2.41M | 2.24M | 1.75M | 1.71M | 1.68M | 940.00K | 363.00K | 361.00K | 338.00K | 329.71K | 376.81K | 337.03K | 283.95K | 245.27K | 322.04K |
| EBITDA | -14.02M | -28.12M | -25.72M | -18.35M | -11.74M | -13.95M | -12.48M | -12.53M | -8.91M | -6.30M | -3.31M | -5.86M | -5.35M | -9.28M | -5.73M | -1.62M | -1.62M | -1.34M |
| EBITDA Ratio | -6,231.56% | 0.00% | -1,918.09% | -1,305.74% | -716.54% | -691.18% | -2,811.71% | -3,181.22% | -939.87% | -340.52% | -1,611.71% | -624.63% | -994.23% | -1,312.61% | 0.00% | -139.57% | -164.16% | -149.86% |
| Operating Income | -16.63M | -29.31M | -49.69M | -31.11M | -14.00M | -15.79M | -14.23M | -14.27M | -9.89M | -6.67M | -3.84M | -6.67M | -9.33M | -9.65M | -4.59M | -1.93M | -1.87M | -1.67M |
| Operating Income Ratio | -7,392.89% | 0.00% | -2,085.19% | -1,312.15% | -854.88% | -782.36% | -3,204.28% | -3,622.84% | -1,043.57% | -360.13% | -1,873.17% | -662.07% | -730.19% | -1,856.25% | 0.00% | -163.71% | -189.00% | -185.79% |
| Total Other Income/Expenses | 1.19M | 0.00 | 184.00K | 7.90M | -2.44M | -1.81M | -1.88M | -1.87M | -764.00K | 41.00K | 174.00K | 469.00K | 3.65M | -2.49M | -1.49M | 20.42K | 0.00 | 0.00 |
| Income Before Tax | -15.44M | -29.31M | -50.30M | -23.21M | -16.44M | -17.60M | -16.11M | -16.14M | -10.66M | -6.63M | -3.67M | -6.20M | -5.62M | -12.10M | -6.08M | -1.91M | -1.87M | -1.67M |
| Income Before Tax Ratio | -6,863.56% | 0.00% | -2,110.95% | -979.04% | -1,003.91% | -872.00% | -3,627.93% | -4,096.19% | -1,124.16% | -357.91% | -1,788.29% | -615.49% | -440.34% | -2,327.44% | 0.00% | -161.97% | -189.00% | -185.79% |
| Income Tax Expense | 0.00 | -1.64M | 701.00K | 46.00K | 2.47M | -4.00K | 34.00K | 347.00K | -65.00K | -9.00K | 45.00K | 120.00K | -3.65M | 2.49M | 2.40K | 1.53K | 3.71K | 851.00 |
| Net Income | -24.91M | -29.31M | -51.01M | -23.26M | -18.92M | -17.59M | -16.11M | -14.53M | -9.76M | -6.63M | -3.67M | -6.20M | -5.68M | -12.14M | -6.08M | -1.91M | -1.87M | -1.67M |
| Net Income Ratio | -11,069.78% | 0.00% | -2,140.37% | -980.98% | -1,154.76% | -871.80% | -3,627.25% | -3,688.32% | -1,029.96% | -357.91% | -1,788.29% | -615.49% | -444.35% | -2,334.73% | 0.00% | -162.10% | -189.38% | -185.88% |
| EPS | -6.50 | -47.87 | -116.97 | -59.45 | -80.53 | -70.50 | -37.87 | -40.77 | -30.15 | -23.17 | -14.56 | -31.38 | -35.92 | -98.02 | -55.65 | -23.53 | -19.92 | -17.76 |
| EPS Diluted | -6.50 | -47.87 | -116.97 | -59.45 | -80.53 | -70.50 | -37.87 | -40.77 | -30.15 | -23.17 | -14.56 | -31.38 | -35.92 | -98.02 | -55.65 | -23.53 | -19.92 | -17.76 |
| Weighted Avg Shares Out | 3.83M | 612.25K | 436.05K | 391.25K | 234.90K | 249.54K | 425.24K | 356.44K | 323.89K | 285.98K | 251.87K | 197.52K | 158.02K | 123.88K | 109.21K | 81.06K | 93.83K | 93.83K |
| Weighted Avg Shares Out (Dil) | 3.83M | 612.25K | 436.05K | 391.25K | 234.90K | 249.54K | 425.24K | 356.44K | 323.89K | 285.98K | 251.87K | 197.52K | 158.02K | 123.88K | 109.21K | 81.06K | 93.83K | 93.83K |
Why Is iBio's Stock Trading Higher Today?
iBio, Inc. (NYSE: IBIO) shares are trading higher after the company provided an update on its IBIO-201 program and reported on its progress in developing a second-generation subunit vaccine candidate, IBIO-202, being designed for the prevention of SARS-CoV-2 infection. "Combined...
IBIO Stock: Over 30% Increase Intraday Explanation
The stock price of iBio, Inc. (NYSEA:IBIO) increased by over 30% during at the opening of the stock market today. This is why it happened.
iBio Stock Is Trading Higher After Announcing Next-Gen COVID-19 Vaccine Candidate
iBio Inc (NYSE: IBIO) has provided an update on its IBIO-201 program and reported its progress in developing a second-generation subunit vaccine candidate, IBIO-202, being designed for the prevention of SARS-CoV-2 infection. IBIO-201 combines antigens derived from the spike protein ("S protein") fused with...
iBio Reports Successful COVID-19 Vaccine Toxicology Study Results and Announces Next-Gen COVID-19 Vaccine Program
BRYAN, Texas, May 06, 2021 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, today provided an update on its IBIO-201 program and reported on its progress in developing a second-generation...
Why iBio Stock Soared Today
A landmark legal settlement should bolster the biotech's growth prospects.
A Couple Key Levels To Watch In iBio's Stock
iBio Inc. (NYSE:IBIO) shares gapped higher Wednesday morning after the company announced it successfully resolved its lawsuit with Fraunhofer USA. The resolution confirms iBio's ownership of certain intellectual property related to plant-based biopharmaceutical production.
IBIO Stock: The Big Lawsuit News That Has iBio Shares Rocketing Today
Ibio (IBIO) stock is on the rise Wednesday after announcing an end to its legal battle with Fraunhofer USA and settlement agreement. The post IBIO Stock: The Big Lawsuit News That Has iBio Shares Rocketing Today appeared first on InvestorPlace.
iBio and Fraunhofer USA Conclude Litigation and Enter License Agreement
BRYAN, Texas, May 04, 2021 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, announced today that it has successfully resolved its lawsuit with Fraunhofer USA, Inc. (“Fraunhofer USA”). The parties' settlement confirms iBio's...
7 Pharmaceutical Stocks That Could Get a Covid Hangover
Pharmaceutical stocks gained a lot from the pandemic and the race to vaccines, but most of that upside is off the table now. The post 7 Pharmaceutical Stocks That Could Get a Covid Hangover appeared first on InvestorPlace.
Take Your Profits! 7 Covid Winners to Sell Now
Because of the pandemic, many so-called Covid stocks enjoyed outsized gains but investors might want to consider trimming their exposure. The post Take Your Profits!
Source: https://incomestatements.info
Category: Stock Reports